Gibson Dunn Advises Coastlands Capital on up to $40 Million Financing for AN2 Therapeutics, Inc.
Firm News | March 9, 2026
Gibson Dunn represented Coastlands Capital as lead investor in the up to $40 million private placement financing for AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform.
Gibson Dunn regularly advises life sciences investors on private placement financings for clinical-stage biopharmaceutical companies.
The Gibson Dunn team included Ryan Murr and Branden Berns.